Mipomersen - Wikipedia
Mipomersen (INN; trade name Kynamro) is a drug used to treat homozygous familial hypercholesterolemia and is administered by subcutaneous injection. There is a serious risk of liver damage from this drug and it can only be prescribed in …
Mipomersen - StatPearls - NCBI Bookshelf
2023年7月2日 · Mipomersen is a lipid-lowering drug used in the treatment of homozygous familial hypercholesterolemia. It is an antisense oligonucleotide inhibitor of apolipoprotein B-100. This activity reviews the indications, mechanism of action, and contraindications of mipomersen for managing homozygous familial hypercholesterolemia.
Mipomersen Uses, Side Effects & Warnings - Drugs.com
Mipomersen is a cholesterol-lowering medication. It reduces blood levels of "bad" cholesterol, such as low-density lipoprotein (LDL), apolipoprotein-B (apo-B), or non-high-density lipoprotein (non-HDL).
Mipomersen in Familial Hypercholesterolemia: An Update on …
Mipomersen is an antisense oligonucleotide inhibitor targeted to apolipoprotein B-100 (apoB-100) mRNA that is administered via subcutaneous injection. Once administered, mipomersen causes selective degradation of the apoB-100 mRNA and inhibition of protein translation.
Mipomersen: Uses, Interactions, Mechanism of Action - DrugBank …
2007年11月18日 · Mipomersen is an oligonucleotide drug used for the treatment of homozygous familial hypercholesterolemia. Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide.
Mipomersen (subcutaneous route) - Mayo Clinic
Mipomersen injection is used together with a proper diet and other medicines to treat high cholesterol levels in patients with homozygous familial hypercholesterolemia (HoFH). This medicine is only available through a restricted access program.
Mipomersen (Kynamro): A Novel Antisense Oligonucleotide …
Mipomersen is a novel antisense oligonucleotide inhibitor of apolipoprotein B. It is approved by the FDA only as an orphan drug for use in HoFH, a relatively rare genetic condition. Ongoing clinical trials are being conducted to evaluate the safety and efficacy of …
Mipomersen sodium: first global approval - PubMed
Mipomersen sodium (Kynamro™) (henceforth mipomersen) is a second-generation antisense oligonucleotide inhibitor of apolipoprotein B-100, which is the main structural component of atherogenic lipid particles.
Mipomersen: Dosage, Mechanism/Onset of Action, Half-Life
Mipomersen is an oligonucleotide inhibitor of apo B-100 synthesis. ApoB is the main component of LDL-C and very low density lipoprotein (VLDL), which is the precursor to LDL-C. Mipomersen binds to the messenger ribonucleic acid (mRNA) of apoB in a sequence-specific manner which results in degradation (RNase H-mediated) or disruption of the mRNA ...
Clinical and Preclinical Pharmacokinetics and Pharmacodynamics …
2015年1月6日 · Mipomersen is an antisense oligonucleotide inhibitor of apolipoprotein B-100 synthesis, approved in the US for the treatment of patients with homozygous familial hypercholesterolemia. Mipomersen has consistent and well-characterized pharmacokinetic and pharmacodynamic properties in both animals and humans.
- 某些结果已被删除